george nisyrios | HIV and Viral Hepatitis meeting Sydney 28-29 August
post-template-default,single,single-post,postid-20186,single-format-standard,edgt-core-1.0,ajax_fade,page_not_loaded,,hudson child-child-ver-1.0.0,hudson-ver-1.2, vertical_menu_with_scroll,smooth_scroll,transparent_content,blog_installed,wpb-js-composer js-comp-ver-4.6.2,vc_responsive
Sep 15 2015

HIV and Viral Hepatitis meeting Sydney 28-29 August

Perspectives in Virology HIV and Hepatitis is an annual scientific meeting held in Australia.  The program is established by Professor David Cooper and Professor Stephen Locarnini and funding is provided by Gilead Sciences.

The meeting is historically of very high quality and typically follows the format of a number of plenary presentations by international experts supported by small group case based workshops with the speakers.

The timing of the meeting mid year allows for feedback from important annual scientific conferences held earlier in the year.  Expert plenaries provide an excellent forum for up to date data presentation, analysis and opinion of cutting edge topics in HIV and viral hepatitis.

Stand out presentations for me this year included Dr Karine Lacombe’s(pictured) excellent summary and workshop on HIV/HCV co-infection and the state of play of treatment for these individuals  and Professor Sheena McCormacks’s presentation on HIV pre exposure prophylaxis (PrEP).

Both topics represent rapidly evolving areas of HIV management.

The future of HIV must be focussed on preventing new infections.  Out of many strategies that exist at a population and patient level, PrEP has been shown to be high efficacious in adherent high risk patients.  The cost if prohibitory at the moment for widespread roll out, but this issue is being actively progressed at government funding levels.

With the advent of highly efficacious, easy to tolerate, simple regimens for treating HCV, the future for treating and controlling HCV globally is incredibly exciting. Once again the cost is prohibitory to widespread access to these very new drugs, but there is the expectation that very soon broad access with be available through government funded treatment programs.

Share Post
No Comments

Post a Comment